Healthy volunteers participating in the clinical study NCT03362593 were dosed orally with single or multiple ascending doses of MEDI7219 tablets. Healthy volunteers received enteric coated MEDI7219 tablets containing 200, 400 and 800 mg PG per tablet. The clinical plasma samples were analyzed using the validated method described above. Figure shows representative PG pharmacokinetic data. After oral administration of tablets containing PG, the Tmax of PG was reached around 3-4 hours post-dose. PG exposure (mean AUC0-t and Cmax) generally increased over the study duration with increasing dose levels.